Zobrazeno 1 - 10
of 27
pro vyhledávání: ''
Autor:
Gilberto Lopes
Publikováno v:
BMC Cancer
BMC Cancer, Vol 11, Iss 1, p 178 (2011)
BMC Cancer, Vol 11, Iss 1, p 178 (2011)
Background Trastuzumab has revolutionized the way we treat early Her2Neu-positive breast cancer, as it significantly improves disease-free and overall survival. Little is known about the societal costs and benefits of treatment with trastuzumab in th
Autor:
Jin Seok Ahn, Yoon-La Choi, Hyun Jung Jun, Yeon Hee Park, Myung Hee Chang, Eun Yoon Cho, Min Jae Park, Young-Hyuck Im, Ji Eun Uhm, Do Hyoung Lim, Sang Hoon Ji, Kyoung Ha Kim, Seong Yoon Yi
Publikováno v:
BMC Cancer
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
BMC Cancer, Vol 10, Iss 1, p 527 (2010)
Background We analyzed the responses to first line treatment and clinical outcomes of metastatic breast cancer patients treated with palliative doxorubicin/cyclophosphamide (AC) according to molecular cancer subtype. Methods A retrospective analysis
Publikováno v:
BMC Cancer
BMC Cancer, Vol 12, Iss 1, p 257 (2012)
BMC Cancer, Vol 12, Iss 1, p 257 (2012)
Background Sulfotransferase 1A1 (SULT1A1) participates in the elimination of 4-hydroxy-tamoxifen (4-OH-TAM), which is one of the major active metabolites of tamoxifen (TAM). Homozygous SULT1A1 variant allele genotype has been associated with lower ca
Publikováno v:
BMC Cancer
Background This analysis was undertaken to evaluate the practice patterns of Japanese physicians regarding curative-intent chemotherapy, especially in outpatient settings, and to define factors negatively affecting the maintenance of relative dose in
Autor:
Taijiro Kosaka, Masahiko Tanabe, Atsushi Arakawa, Hiroshi Sonoue, Fumie Igari, Hideo Shimizu, Koji Senuma, Emi Tokuda, Yoshiya Horimoto, Mitsue Saito
Publikováno v:
BMC Cancer
Background Patients with luminal HER2-negative tumours have a favourable prognosis. However, there is a subpopulation in which poorer outcomes are obtained with endocrine therapy alone. This subpopulation is considered to benefit from chemotherapy. H
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-13 (2017)
BMC Cancer, 17(232). BMC
BMC Cancer
BMC Cancer, 17(232). BMC
BMC Cancer
Background Clinical efficacy of the mTOR inhibitor everolimus is limited in breast cancer and regularly leads to side-effects including hyperglycemia. The AMPK inhibitor and anti-diabetic drug metformin may counteract everolimus-induced hyperglycemia
Autor:
Chiara Campanella, Monica Gatti, Tullio Florio, Valeria Marini, Aldo Pagano, Guendalina Vito, Antonio Daga, Alessandra Pattarozzi, Alessandra Ratto, Francesca Mattioli, Adriana Bajetto, Roberto Würth, Carmen Fucile, Angelo Ferrari, Federica Barbieri, Elisa Carra, Stefano Thellung
Publikováno v:
BMC Cancer
Background Cancer stem cells (CSCs) are considered the cell subpopulation responsible for breast cancer (BC) initiation, growth, and relapse. CSCs are identified as self-renewing and tumor-initiating cells, conferring resistance to chemo- and radio-t
Autor:
Sharon X. Xie, John T. Farrar, Kannie Chim, Angela DeMichele, Jun J. Mao, Robert E. Gross, Qing S. Li, Carrie Tompkins Stricker
Publikováno v:
BMC Cancer
Background Premature discontinuation of aromatase inhibitors (AIs) in breast cancer survivors compromises treatment outcomes. We aimed to evaluate whether patient-reported joint pain predicts premature discontinuation of AIs. Methods We conducted a r
Autor:
Guilhem Bousquet, Nathalie Jourdan, Cathy Pereira, Anne Janin, Diaddin Hamdan, Christophe Leboeuf, Laurence Verneuil
Publikováno v:
BMC Cancer
BMC Cancer, BioMed Central, 2015
BMC Cancer, BioMed Central, 2015
Background Hypereosinophilia, defined by an absolute eosinophil count of more than 1500/mm3, is rarely observed in patients treated for cancer, and rarely imputable to anti-cancer agents. Drug-induced hypereosinophilia usually appears within a few we
Autor:
Joshua Matthew Rhett, Gautam S. Ghatnekar, Jaclynn S. Bruce, Elizabeth S. Yeh, Christina L. Grek, Melissa A. Abt
Publikováno v:
BMC Cancer
Background Treatment failure is a critical issue in breast cancer and identifying useful interventions that optimize current cancer therapies remains a critical unmet need. Expression and functional studies have identified connexins (Cxs), a family o